Изучение содержания адипокинов крови у больных с первым приступом шизофрении

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Озорнин А.С., Говорин Н.В., Сахаров А.В., Терешков П.П. Изучение содержания адипокинов крови у больных с первым приступом шизофрении // Российский психиатрический журнал. 2020. №5. С. 96-102.

Аннотация

В одномоментном экспериментальном исследовании с целью изучения содержания адипокинов в крови у больных шизофренией было обследовано 212 пациентов с диагнозом F20.09 («шизофрения параноидная, период наблюдения менее года»), в качестве контрольной группы – 132 здоровых человека. Выявлено, что у больных с первым эпизодом шизофрении величина адипонектина превышала контрольные значения в 2,3 раза, адипсина – в 2,5 раза. Количество лептина крови было повышено только у больных женского пола. Увеличение содержания адипокинов у пациентов с шизофренией может являться одним из звеньев патогенеза этого заболевания, а также обусловливать нарушения углеводного и липидного обменов, способствуя формированию метаболического синдрома при психофармакотерапии.

Ключевые слова шизофрения; первый эпизод; адипонектин; лептин; резистин; адипсин

Литература

1. Dedov II, Mel'nichenko GA, Butrova SA. Zhirovayatkan' kakendokrinnyi organ. Ozhirenie i metabolism [Obesity and Metabolism]. 2006;(1):6–13. Russian. 2. Boyarinova MA, Rotar' OP, Konradi AO. [Adipokines and cardiometabolic syndrome]. Arterial'naya gipertenziya [Arterial Hypertension]. 2014;20(5):422–32. Russian. 3. Kirienkova EV, Vasilenko MA, Skuratovskaya DA, et al. [New pathogenetic factors in formation of metabolic inflammation]. Russ J Immunol. 2015;9(3):283–97. Russian. 4. Naderyan Fe'li S, Yassini Ardekani SM, Fallahzadeh H, et al. Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics. Med J Islam Repub Iran. 2019;(33):97. DOI: https://doi.org/10.34171/mjiri.33.97; PMID: 31696091; PMCID: PMC6825382 5. Heald A, Pendlebury J, Anderson S, et al. Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study. Ann Gen Psychiatry. 2017;(16):12. DOI: https://doi.org/10.1186/s12991-017-0134-6; PMID: 28289436; PMCID: PMC5310063 6. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;(47):64–6. DOI: https://doi.org/10.1192/bjp.184.47.s64; PMID: 15056595 7. Ozornin AS, Ozornina NV, Govorin NV. [Some pathophysiological mechanisms of lipid profile changes in patients with acute schizophrenia treated with antipsychotics]. Sotsial'naya i klinicheskaya psikhiatriya. 2013;23(2):45–9. Russian. 8. Ozornin AS, Ozornina NV, Govorin NV, et al. [Features of erythrocyte membrane fatty acid content in first-epizode schizophrenia patients]. Zabaikal'skii meditsinskii vestnik [The transbaikalian medical bulletin]. 2011;(1):12–4. Russian. 9. Bartoli F, Lax A, Crocamo C, et al. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology. 2015;(56):179–89. DOI: https://doi.org/10.1016/j.psyneuen.2015.03.012; PMID: 25827962 10. Lee EE, Sears DD, Liu J, et al. A novel biomarker of cardiometabolic pathology in schizophrenia? J Psychiatr Res. 2019;(117):31–7. DOI: https://doi.org/10.1016/j.jpsychires.2019.06.011; PMID: 31276836; PMCID: PMC6707833 11. Song X, Fan X, Song X, et al. Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. Schizophr Res. 2013;150(1):269–73. DOI: https://doi.org/10.1016/j.schres.2013.07.044; PMID: 23968860 12. Hönig GJ. Esquizofrenia y antipsicóticos: alteracionesmetabólicas y efectividadterapéutica. Schizophrenia and antipsychotics: Metabolic alterations and therapeutic effectivity. Vertex. 2018;29(138):139–47. PMID: 30605187 13. Beumer W, Drexhage RC, De Wit H, et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11. DOI: https://doi.org/10.1016/j.psyneuen.2012.04.001; PMID: 22541717 14. Toussirot É, Binda D, Gueugnon C, et al. Adiponectin in autoimmune diseases. Curr Med Chem. 2012;19(32):5474–80. DOI: https://doi.org/10.2174/092986712803833119; PMID: 22876925 15. Scotece M, Conde J, López V, et al. Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol. 2014;114(1):97–102. DOI: https://doi.org/10.1111/bcpt.12109; PMID: 23834523 16. Liu D, Luo S, Li Z. Multifaceted roles of adiponectin in rheumatoid arthritis. Int Immunopharmacol. 2015;28(2):1084–90. DOI: https://doi.org/10.1016/j.intimp.2015.08.013; PMID: 26307192 17. Parfenova NS, Tanyanskii DA. [Adiponectin: beneficial effects on metabolic and cardiovascular dysfunctions]. Arterial'naya gipertenziya [Arterial Hypertension]. 2013;19(1):85–96. Russian. 18. Kovaleva YuV. [Adipose tissue hormones and their role for female fertility and metabolic disorders]. Arterial'naya gipertenziya [Arterial Hypertension]. 2015;21(4):356–70. Russian. DOI: https://doi.org/10.18705/1607-419X-2015-21-4-356-370 19. Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. Obes Rev. 2013;14(12):939–49. DOI: https://doi.org/10.1111/obr.12064; PMID: 23957239 20. Ebinuma H, Miida T, Yamauchi T, et al. Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid. Clin Chem. 2007;53(8):1541–4. DOI: https://doi.org/10.1373/clinchem.2007.085654; PMID: 17599956 21. Bednarska-Makaruk M, Graban A, Wiśniewska A, et al. Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. Biogerontology. 2017;18(4):561–80. DOI: https://doi.org/10.1007/s10522-017-9701-0; PMID: 28421328; PMCID: PMC5514216 22. Misiak B, Bartoli F, Stramecki F, et al. Appetite regulating hormones in first-episode psychosis: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;(102):362–70. DOI: https://doi.org/10.1016/j.neubiorev.2019.05.018; PMID: 31121198 23. Martorell L, Muntané G, Porta-López S, et al. Increased levels of serum leptin in the early stages of psychosis. J Psychiatr Res. 2019;(111):24–9. DOI: https://doi.org/10.1016/j.jpsychires.2019.01.006; PMID: 30660810 24. Wędrychowicz A, Zając A, Pilecki M, et al. Peptides from adipose tissue in mental disorders. World J Psychiatry. 2014;4(4):103–11. DOI: https://doi.org/10.5498/wjp.v4.i4.103; PMID: 25540725; PMCID: PMC4274582 25. Maramygin DS, Sumenkova DV, Sitnikov RV. Adipokiny v patogeneze metabolicheskogo sindroma. Mezhdunarodnyi nauchnyi zhurnal “Innovatsionnaya nauka”. 2017;4(3):197–207. Russian. 26. Zahary MN, Harun NS, Yahaya R, et al. Serum adiponectin and resistin: Correlation with metabolic syndrome and its associated criteria among temiarsubtribe in Malaysia. Diabetes Metab Syndr. 2019;13(3):2015–9. DOI: https://doi.org/10.1016/j.dsx.2019.04.048; PMID: 31235129 27. Balõtšev R, Haring L, Koido K, et al. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. Early Interv Psychiatry. 2019;13(1):101–9. DOI: https://doi.org/10.1111/eip.12457; PMID: 28719155 28. Sahpolat M, Ari M, Kokacya MH. Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia. Clin Psychopharmacol Neurosci. 2020;18(1):109–15. DOI: https://doi.org/10.9758/cpn.2020.18.1.109; PMID: 31958911; PMCID: PMC7006973 29. Vasilenko MA, Kirienkova EV, Skuratovskaya DA, et al. Rol' produktsii adipsinaileptina v formirovanii insulinorezistentnosti u bol'nykh abdominal'nym ozhireniem. Doklady akademiinauk. 2017;475(3):336–41. Russian. 30. Ohtsuki T, Satoh K, Shimizu T, et al. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. J Am Heart Assoc. 2019;8(23):1–14. DOI: https://doi.org/10.1161/JAHA.119.013716; PMID: 31752640; PMCID: PMC6912964 31. Guo D, Yuan Y, Huang R, et al. Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study. BMC Endocr Disord. 2019;19(1):108. DOI: https://doi.org/10.1186/s12902-019-0431-y; PMID: 31651303; PMCID: PMC6814099



DOI: http://dx.doi.org/10.24411/1560-957Х-2020-10511

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM